The Centers for Medicare & Medicaid Services on Tuesday morning announced the must-anticipated list of the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act.

The list includes Eliquis, a Bristol-Myers Squibb drug to prevent blood clots used by more than 3.7 million people on Medicare in the year ending May 2023 at a cost of $16.4 billion to the program, and Xarelto, another blood thinner, made by Johnson & Johnson that is used by more than 1.3 million people on Medicare at a cost to the program of more than $6 billion.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.